Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

Xintela AB: BioStock: Xintela's strategy for 2023

Xintela

2022 was an eventful and successful year for Xintela. The company entered into clinical development for the treatment of knee osteoarthritis and difficult-to-heal venous leg ulcers and thus has two ongoing clinical phase I/IIa studies with XSTEM. In addition, further development of EQSTEM for the treatment of joint diseases in horses is planned. In parallel with the stem cell projects, a phase 0 study is being prepared in the subsidiary Targinta. Xintela's CEO Evy Lundgren-Åkerlund tells us more about the plans for 2023 in an interview with BioStock.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/02/xintelas-strategy-for-2023/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.